A new state of the art, GMP-ready clinical manufacturing site is now ready in South Brunswick.
On Jan. 26, BioCentriq announced it completed construction on the 9,000-square-foot facility at 7 Deer Park Drive. According to Senior Vice President and General Manager Haro Hartounian, the expanded clinical production capacity will help the company meet its clients’ demands.
“We understand the myriad challenges our clients face when they are optimizing and scaling up their processes to prepare for clinical manufacturing,” he said. “Our team’s cumulative expertise in process development and GMP manufacturing enables us to meet the growing demand in this space.”
The new facility is located adjacent to BioCentriq’s existing pilot plant. According to the company, it offers supporting infrastructure and lab space for the clinical manufacturing of allogeneic and autologous cell therapies and gene therapies.
Initial projects are expected to begin at the new facility early in the third quarter of 2022, after the facility has been validated and commissioned.
Amid COVID-19, much of the industry’s manufacturing capacity has been redirected to vaccine production, while growth continues in the development of personalized medicines, BioCentriq said. According to the Alliance of Regenerative Medicine, as of the third quarter of 2021 there were more than 2,200 ongoing clinical trials and market research firms regularly estimate compounded annual growth rates at greater than 20%.